Otsuka Wins Patent Ruling Blocking Lonsurf Copies Until 2029

Otsuka Holdings Co.’s Taiho unit won a ruling upholding a patent for Lonsurf that could block copies of the metastatic colorectal cancer treatment proposed by generic-drug makers including Aurobindo Pharma Ltd. for another six years.

Judge Colm F. Connolly, in an opinion issued Tuesday in the US District Court for the District of Delaware, rejected arguments by Aurobindo’s Eugia Pharma Specialties Ltd., Intas Pharmaceuticals Ltd.'s Accord Healthcare Ltd., MSN Laboratories Private Ltd., and Natco Pharma Ltd. that the patent should be voided.

The generic-drug makers already had conceded before a two-day bench trial in March that ...